User
Our local employees are always happy to answer your questions. Highly trained and experienced teams in your country can provide quick, helpful, and comprehensive support.
Miltenyi Biotec Inc.
2303 Lindbergh Street
Auburn, CA 95602
USA
Phone: +1 800 FOR MACS
+1 530 888 8871
Fax: +1 530 888 8925
E-Mail: macs@miltenyibiotec.com
Web: www.miltenyibiotec.com
For immediate technical support, use our live chat. Connect with us
Orders
Phone: +1 866 811 4466
Fax: +1 877 591 1060
E-Mail: orderdesk@miltenyibiotec.com
Technical support - Research products
Phone: +1 800 FOR MACS
Fax: +1 530 745 2806
E-Mail: science@miltenyibiotec.com
Technical support - Clinical products
Phone: +1 800 FOR MACS
Fax: +1 530 745 2806
E-Mail: science@miltenyibiotec.com
As a global market leader with numerous subsidiaries and distributors, Miltenyi Biotec is committed to providing our customers around the world with the highest quality products. In addition to direct selling in more than 20 countries in North America, Europe and Asia/Pacific, Miltenyi Biotec also provides support for our customers through an extensive distributor network covering dozens of additional countries.
There are two main types of stem cell transplants – allogeneic and autologous. An allogeneic stem cell transplant is a procedure in which a patient receives blood-forming stem cells from a donor. In contrast, for an autologous stem cell transplant, the patient provides his own stem cells for the procedure. Blood stem cells collected from the patient while he is in remission are stored and then returned following conditioning chemotherapy or radiation.
The rationale for allogeneic stem cell transplantation is two-fold. A chemotherapy or radiation-based treatment before transplantation, called conditioning, enables the elimination of the harmful leukemic cells. An undesirable effect however is the destruction of the patient’s immune and blood building systems
Therefore, the first goal of allogeneic stem cell transplantation is to replace the patient’s blood and immune system with a healthy one from a donor. The second goal and major advantage of this approach is that newly generated immune cells attack residual leukemic cells, called the graft-versus-leukemia (GvL) effect. This makes the disease less likely to return.
Stem cells can be collected from bone marrow, the blood stream (peripheral blood stem cells), or umbilical cord blood. Harvesting stem cells from bone marrow was the original collection method and has the longest history in stem cell transplantation. Frequently “bone marrow transplantation” is used as the umbrella term for stem cell transplantation. The transplanted cells are called the “graft”
Our blood cells develop from a small number of precursor bone marrow cells called blood stem cells. These stem cells have not committed to a specific blood cell type. Blood stem cells will develop into white blood cells, red blood cells, or platelets in the presence of specific chemical signals.
White blood cells are cells of the immune system with the function to fight infections caused by bacteria, viruses, and fungi.
Red blood cells carry oxygen from the lungs to the cells in the body
Platelets, also called thrombocytes, are pieces of cells that seal damaged blood vessels and help blood to clot. Both functions are important in stopping bleeding.
Following a successful stem cell transplant, the bone marrow is repopulated with blood stem cells from the healthy donor, which will rebuild the patient’s blood and immune systems. This step is critical for the effective treatment of AML.
Humanitarian Device
Authorized by U.S. Federal Law for use in the treatment of patients with acute myeloid leukemia (AML) in first complete remission. The effectiveness of the device for this use has not been demonstrated.
Indications for Use
The CliniMACS® CD34 Reagent System is indicated for processing hematopoietic progenitor cells collected by apheresis (HPC, Apheresis) from an allogeneic, HLA-identical, sibling donor to obtain a CD34+ cell-enriched population for hematopoietic reconstitution following a myeloablative preparative regimen without the need for additional graft versus host disease (GVHD) prophylaxis in patients with acute myeloid leukemia (AML) in first morphologic complete remission.
Contraindications
Do not use CD34+ cells prepared with CliniMACS CD34 Reagent System in patients with known hypersensitivity to murine (mouse) proteins or iron dextran.
Rx only
View details
